Oral, fixed dose combination of 300 mg of netupitant, a highly selective NK1 receptor antagonist, and 0.5 mg of palonosetron a distinct 5-HT3 receptor antagonist, for the prevention of chemotherapy induced nausea and vomiting (CINV).
A single pill alternative to multi agent antiemetic regimens for CINV.
This drug combination is superior to oral palonosetron for prevention of CINV in highly emetogenic chemotherapy.
Efficacious and well tolerated.